<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607087</url>
  </required_header>
  <id_info>
    <org_study_id>APIDR_C_02083</org_study_id>
    <secondary_id>2007-003579-38</secondary_id>
    <nct_id>NCT00607087</nct_id>
  </id_info>
  <brief_title>Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus</brief_title>
  <acronym>PUMP</acronym>
  <official_title>Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart
      and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or
      infusion set occlusion.

      Main Secondary objectives:

      To compare insulin glulisine, insulin aspart and insulin lispro on:

        -  Unexplained hyperglycemia

        -  Infusion set occlusion

        -  Hypoglycemic episodes,7-point blood glucose profiles

        -  Episodes of significant ketosis and/or risk level for impending diabetic ketoacidosis

        -  Time to change the infusion set

        -  HbA1c (Glycosylated hemoglobin)

        -  Overall safety: incidence of adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximal duration of the study participation for patients was 41 weeks and one day, split
      in:

        -  a 2-week screening period,

        -  a 39-week treatment period: 3 treatment periods of 13 weeks with a crossover alternative
           regimen, including a dose adjustment period of 1 week at the beginning of each period
           (sequence1: insulin glulisine, then insulin aspart, then insulin lispro; sequence2:
           insulin aspart, then insulin lispro, then insulin glulisine; sequence 3: insulin lispro,
           then insulin glulisine, then insulin aspart)

        -  and a follow-up period of 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With at Least One Unexplained Hyperglycemia</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly Rate of Unexplained Hyperglycemia</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With at Least One Confirmed Infusion Set Occlusion</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly Rate of Confirmed Infusion Set Occlusion</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe Symptomatic Hypoglycemia Per Patient-year</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following:
the event was associated with a measured blood glucose level below 36 mg/dL
or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment.
Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment.
Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection.
Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Interval Between Infusion Set Changes: All Changes</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
&quot;All changes&quot; include all the changes whatever the reason such as routine or requested by occurrence of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Interval Between Infusion Set Changes in Routine</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
Changes in routine correspond to interval between changes according to patient use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Hemoglobin: HbA1c</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Basal Insulin Infusion</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>dose of the basal insulin regimen administered throughout the 24-hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Bolus Insulin Dose</measure>
    <time_frame>over 13 weeks of each treatment period</time_frame>
    <description>dose of every increment administered for example before meals</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 1: insulin glulisine / insulin aspart / insulin lispro.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2: insulin aspart / insulin lispro / insulin glulisine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3: insulin lispro / insulin glulisine / insulin aspart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetic subjects

          -  Treated with insulin for at least 2 years and by CSII for at least 6 months

          -  Using the same insulin (insulin glulisine, insulin aspart or insulin lispro) in CSII
             for at least 3 months with the same external pump compatible with the 3 short acting
             insulin analogues used in the study

          -  Using the same type of infusion set (catheter and cannula) for at least 3 months

          -  Performing at least 3 blood glucose controls per day

          -  HbA1c &lt; 8.5%

          -  Body mass index (BMI) &lt; 35 kg/m²

          -  Ability and willingness to perform blood glucose and ketone monitoring using the
             Sponsor-provided combined glucose and ketone meter and patient diary at home

        Exclusion Criteria:

          -  Diabetes other than Type 1

          -  Total daily dose of insulin greater than 90 U/day

          -  Using an insulin pump requiring pre-filled cartridges

          -  History of infection at infusion site requiring a drainage in the last 3 months

          -  History of severe episodes of ketosis requiring hospitalization in the last 6 months

          -  Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy
             occurrence in the 6 months prior to visit 1, or any other unstable (rapidly
             progressing) retinopathy that may require photocoagulation or surgical treatment
             during the study. An ophthalmoscopic examination should have been performed in the 2
             years prior to study entry

          -  Pregnancy (women of childbearing potential must have a negative pregnancy test at
             study entry and a medically approved contraception method) or breastfeeding

          -  Treatment with systemic corticosteroids or medication known to influence insulin
             sensitivity in the 3 months prior to visit 1

          -  Treatment with antidiabetic drug other than insulin in the 3 months prior to visit 1

          -  Likelihood of requiring treatments during the study which are not permitted

          -  Treatment with an investigational product in the 30 days prior to visit 1

          -  History of sensitivity to the study drugs or to drugs with a similar chemical
             structure

          -  Presence of any condition (medical, including clinically significant abnormal
             laboratory test, psychological, social or geographical) actual or anticipated that the
             Investigator feels would compromise the patient safety or limit his/her successful
             participation in the study

          -  Night shift workers

          -  Impaired renal function as shown by serum creatinine ≥1.5 mg/dL (133 μmol/L) or ≥1.4
             mg/dL (124 μmol/L) in men and women, respectively

          -  Impaired hepatic function as shown by Alanine aminotransferase (ALT) and/or Aspart
             aminotransferase (AST) greater than three times the upper limit of normal range)

          -  Alcohol or drug abuse in the last year

          -  Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>PE Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <results_first_submitted>June 30, 2010</results_first_submitted>
  <results_first_submitted_qc>June 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter study: 44 active centers from 12 countries in Europe, USA and Asia Pacific region. Study Initiation date: January 8, 2008, Study Completion Date: June 15, 2009.</recruitment_details>
      <pre_assignment_details>359 participants screened; 289 randomized; 288 patients treated (1 patient not treated per physician's decision): 274 with insulin glulisine, 269 with insulin lispro, 266 with insulin aspart.
The safety population, (N=288 patients randomized and treated) is described in the participant flow and baseline characteristics.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>insulin glulisine / insulin aspart / insulin lispro</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>insulin aspart / insulin lispro / insulin glulisine</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>insulin lispro / insulin glulisine / insulin aspart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1</title>
          <description>insulin glulisine / insulin aspart / insulin lispro</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2</title>
          <description>insulin aspart / insulin lispro / insulin glulisine</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3</title>
          <description>insulin lispro / insulin glulisine / insulin aspart</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="94"/>
            <count group_id="B4" value="288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.45" spread="13.71"/>
                    <measurement group_id="B2" value="45.84" spread="13.59"/>
                    <measurement group_id="B3" value="44.04" spread="12.87"/>
                    <measurement group_id="B4" value="44.43" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous insulin at study entry</title>
          <description>Total patients analyzed n=287 due to one missing data in the &quot;sequence 2&quot; group</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Insulin glulisine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin aspart</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin lispro</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of treatment with previous insulin at study entry</title>
          <description>Total patients analyzed n=286 due to one missing data in the &quot;sequence 1&quot; and in the &quot;sequence 2&quot; groups</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.84" spread="3.58"/>
                    <measurement group_id="B2" value="4.37" spread="3.05"/>
                    <measurement group_id="B3" value="4.79" spread="3.00"/>
                    <measurement group_id="B4" value="4.67" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of treatment with insulin at study entry</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.39" spread="13.53"/>
                    <measurement group_id="B2" value="23.07" spread="13.33"/>
                    <measurement group_id="B3" value="22.75" spread="11.08"/>
                    <measurement group_id="B4" value="22.73" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total daily bolus insulin dose</title>
          <description>Total patients analyzed n=285 due to 3 missing data: 2 in the &quot;sequence 1&quot; and 1 in the &quot;sequence 2&quot; groups</description>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.61" spread="9.40"/>
                    <measurement group_id="B2" value="18.58" spread="10.34"/>
                    <measurement group_id="B3" value="19.35" spread="7.78"/>
                    <measurement group_id="B4" value="19.18" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of treatment with CSII (continuous subcutaneous insulin infusion) at study entry</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.99" spread="4.83"/>
                    <measurement group_id="B2" value="5.52" spread="5.27"/>
                    <measurement group_id="B3" value="6.31" spread="4.95"/>
                    <measurement group_id="B4" value="5.94" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total daily basal insulin infusion</title>
          <description>Total patients analyzed n=285 due to 3 missing data: 2 in the &quot;sequence 1&quot; and 1 in the &quot;sequence 2&quot; groups</description>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.98" spread="8.84"/>
                    <measurement group_id="B2" value="19.99" spread="9.38"/>
                    <measurement group_id="B3" value="22.03" spread="9.17"/>
                    <measurement group_id="B4" value="21.00" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.01" spread="3.53"/>
                    <measurement group_id="B2" value="25.25" spread="3.91"/>
                    <measurement group_id="B3" value="25.92" spread="3.98"/>
                    <measurement group_id="B4" value="25.39" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central fasting plasma glucose</title>
          <description>Total patients analyzed n=284 due to 4 missing data: 2 in the &quot;sequence 1&quot; and 2 in the &quot;sequence 3&quot; groups</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149.84" spread="59.03"/>
                    <measurement group_id="B2" value="147.45" spread="61.63"/>
                    <measurement group_id="B3" value="151.18" spread="64.06"/>
                    <measurement group_id="B4" value="149.48" spread="61.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.38" spread="0.69"/>
                    <measurement group_id="B2" value="7.36" spread="0.61"/>
                    <measurement group_id="B3" value="7.41" spread="0.69"/>
                    <measurement group_id="B4" value="7.38" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</title>
        <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</title>
          <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="62.7" upper_limit="74.1"/>
                    <measurement group_id="O2" value="62.1" lower_limit="56.2" upper_limit="68.1"/>
                    <measurement group_id="O3" value="61.3" lower_limit="55.4" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025.</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</title>
        <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion</title>
          <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events per patient per month</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.15"/>
                    <measurement group_id="O2" value="1.32" spread="0.15"/>
                    <measurement group_id="O3" value="1.54" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With at Least One Unexplained Hyperglycemia</title>
        <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least One Unexplained Hyperglycemia</title>
          <description>Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" lower_limit="55.4" upper_limit="67.3"/>
                    <measurement group_id="O2" value="55.9" lower_limit="49.8" upper_limit="61.9"/>
                    <measurement group_id="O3" value="56.3" lower_limit="50.2" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monthly Rate of Unexplained Hyperglycemia</title>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Monthly Rate of Unexplained Hyperglycemia</title>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events per patient per month</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.13"/>
                    <measurement group_id="O2" value="1.04" spread="0.13"/>
                    <measurement group_id="O3" value="1.23" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With at Least One Confirmed Infusion Set Occlusion</title>
        <description>Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least One Confirmed Infusion Set Occlusion</title>
          <description>Pump infusion set occlusion defined by at least one of the following items:
pump occlusion alarm,
patient observation of an occlusion, spontaneously or because of elevated blood glucose value.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="27.1" upper_limit="38.6"/>
                    <measurement group_id="O2" value="27.0" lower_limit="21.5" upper_limit="32.4"/>
                    <measurement group_id="O3" value="27.0" lower_limit="21.5" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.063</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monthly Rate of Confirmed Infusion Set Occlusion</title>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Monthly Rate of Confirmed Infusion Set Occlusion</title>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events per patient per month</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.06"/>
                    <measurement group_id="O2" value="0.28" spread="0.06"/>
                    <measurement group_id="O3" value="0.31" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</title>
        <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</title>
          <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="12.9" upper_limit="22.2"/>
                    <measurement group_id="O2" value="10.9" lower_limit="7.1" upper_limit="14.8"/>
                    <measurement group_id="O3" value="11.7" lower_limit="7.8" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</title>
        <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis</title>
          <description>Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria).
Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and &gt;1.5 mmol/l</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events per patient per month</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.43"/>
                    <measurement group_id="O2" value="0.06" spread="0.22"/>
                    <measurement group_id="O3" value="0.06" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year</title>
        <description>Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year</title>
          <description>Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events in patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.88" spread="4.74"/>
                    <measurement group_id="O2" value="65.06" spread="4.74"/>
                    <measurement group_id="O3" value="62.74" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Severe Symptomatic Hypoglycemia Per Patient-year</title>
        <description>Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following:
the event was associated with a measured blood glucose level below 36 mg/dL
or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Symptomatic Hypoglycemia Per Patient-year</title>
          <description>Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following:
the event was associated with a measured blood glucose level below 36 mg/dL
or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events in patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.35"/>
                    <measurement group_id="O2" value="1.39" spread="0.35"/>
                    <measurement group_id="O3" value="1.07" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.563</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year</title>
        <description>Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year</title>
          <description>Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>events in patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.80" spread="0.95"/>
                    <measurement group_id="O2" value="9.66" spread="0.95"/>
                    <measurement group_id="O3" value="9.48" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site</title>
        <description>Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment.
Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment.
Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection.
Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site</title>
          <description>Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment.
Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment.
Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection.
Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.701</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Interval Between Infusion Set Changes: All Changes</title>
        <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
&quot;All changes&quot; include all the changes whatever the reason such as routine or requested by occurrence of events.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Time Interval Between Infusion Set Changes: All Changes</title>
          <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
&quot;All changes&quot; include all the changes whatever the reason such as routine or requested by occurrence of events.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="20.70"/>
                    <measurement group_id="O2" value="69.44" spread="19.22"/>
                    <measurement group_id="O3" value="69.98" spread="21.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Interval Between Infusion Set Changes in Routine</title>
        <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
Changes in routine correspond to interval between changes according to patient use.</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Time Interval Between Infusion Set Changes in Routine</title>
          <description>Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event).
Changes in routine correspond to interval between changes according to patient use.</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.72" spread="21.47"/>
                    <measurement group_id="O2" value="71.00" spread="20.68"/>
                    <measurement group_id="O3" value="71.07" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Hemoglobin: HbA1c</title>
        <description>Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin: HbA1c</title>
          <description>Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First week (week 1) (n=253, n=254, n=255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.71"/>
                    <measurement group_id="O2" value="7.33" spread="0.71"/>
                    <measurement group_id="O3" value="7.28" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last week (week 13) (n=252, n=255, n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="0.03"/>
                    <measurement group_id="O2" value="7.25" spread="0.03"/>
                    <measurement group_id="O3" value="7.33" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted on HbA1c value at the start of the first period</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.938</p_value>
            <p_value_desc>The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is &lt;0.025</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted on HbA1c level at the start of the first period</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Basal Insulin Infusion</title>
        <description>dose of the basal insulin regimen administered throughout the 24-hour period</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Basal Insulin Infusion</title>
          <description>dose of the basal insulin regimen administered throughout the 24-hour period</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First week (week 1) (n=251, n=249, n=250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="9.05"/>
                    <measurement group_id="O2" value="20.93" spread="9.45"/>
                    <measurement group_id="O3" value="20.85" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last week (week 13) (n=251, n=249, n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.86" spread="9.24"/>
                    <measurement group_id="O2" value="20.81" spread="9.73"/>
                    <measurement group_id="O3" value="21.11" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Bolus Insulin Dose</title>
        <description>dose of every increment administered for example before meals</description>
        <time_frame>over 13 weeks of each treatment period</time_frame>
        <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
          <group group_id="O3">
            <title>Insulin Lispro</title>
            <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Bolus Insulin Dose</title>
          <description>dose of every increment administered for example before meals</description>
          <population>Analysis was performed on the Intention To Treat (ITT) population. The Intent-To-Treat population is composed of all randomized patients having received the 3 insulins (Insulin glulisine, aspart and lispro) N=256 patients: (sequence 1: N=86, sequence 2: N=86; sequence 3: N=84 patients).</population>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First week (week 1) (n=249, n=247, n=250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.63" spread="9.22"/>
                    <measurement group_id="O2" value="18.49" spread="9.00"/>
                    <measurement group_id="O3" value="18.40" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last week (week 13) (n=248, n=244, n=249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.58" spread="8.49"/>
                    <measurement group_id="O2" value="18.64" spread="9.60"/>
                    <measurement group_id="O3" value="19.19" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from the first to the last drug intake (3 periods x 13 weeks) + 1 week after the administration of the last intake i.e. end of the study.</time_frame>
      <desc>The safety analyses are performed on the safety population which includes all randomized and treated patients. Safety population is defined based on actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glulisine</title>
          <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
        </group>
        <group group_id="E2">
          <title>Insulin Aspart</title>
          <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
        </group>
        <group group_id="E3">
          <title>Insulin Lispro</title>
          <description>100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arteritis coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>cardiovascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>ketosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Study Director</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>publicregistryGMA@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

